Abstract Body

Background: To determine in populations at high risk of HIV infection, whether screening of pooled anti-HIV negative specimens for HIV RNA identifies more acute infections than testing specimens by 4th generation assays. To confirm the limitations of 3rd generation screening in high risk populations and discuss its implications for point of care testing.

Methods: Analysis involved 3570 specimens from men who have sex with men (MSM) from two central London STI Clinics and 1837 specimens from heterosexual men of black African ethnicity from a further 2 STI clinics. All specimens had been found to be anti-HIV negative by a 3rd generation anti-HIV assay and were aliquoted to create mini-pools of 8 specimens each. 6 mini-pools went into a Master pools which had maximum of 48 specimens. The master pools were then tested using an in-house real time quantitative taqman probe based assay targeting HIV-1 LTR and pol. Reactive pools were broken down to reveal the individual reactive specimen. Any specimens identified as HIV positive by the RNA assay but negative by the third generation ELISA assay were further tested with a 4th generation Ag/Ab assay.

Results: Of the 5407 anti-HIV negative specimens, 6 were found to be HIV RNA positive. In 3rd generation antibody only testing the specimens were clearly negative with a range of activity of 0.041 -0.508 OD/CO. Using the 4th generation HIV antigen/antibody combination assay all six were positive (OD/CO ranges 4.66 – 19.64). All of the six specimens came from men who have sex with men and five of the six came from one centre.

Conclusions: 4th generation screening is the standard of care in the UK and our data does not support the development of a national scheme to screen anti-HIV negative specimens for HIV RNA. The benefits of RNA screening such as potential earlier diagnosis maybe outweighed by the increased turnaround time for pooled RNA testing and the potential loss to follow up by this delay. However, in a high throughput laboratory that screens a high incidence population, a local application of pooled RNA testing may be applicable. The increasing use of home testing and point of care tests that are often only 3rd generation in nature is of more concern as those acutely infected, and therefore at their most infectious, may be missed and our data supports that 4th gen formats for HIV screening programmes will avoid missing diagnosis.